BioCentriq News and Resources

BioCentriq has announced a strategic collaboration with Orchestra Life Sciences, aimed at optimizing its $12 million investment in a new cell therapy facility in Princeton, New Jersey. The 60,000 sq. ft. site, expected to be fully operational by Q2 2025,

BioCentriq, a CDMO specialising in cell therapy, has entered into a long-term lease for a new state-of-the-art facility in Princeton, New Jersey. This facility, spanning 60,000 square feet, will serve as the company’s headquarters and strengthen its position in the

BioCentriq has appointed Syed T. Husain as its new Chief Executive Officer (CEO) and a member of the Board of Directors, marking a new chapter in the company’s growth in the cell and gene therapy (CGT) sector. Husain, a veteran

BioCentriq, a cell therapy Contract Development and Manufacturing Organisation (CDMO), has announced a significant enhancement to its partnership with Pluristyx Inc., an early-stage biotechnology company specialising in Induced Pluripotent Stem Cell (iPSC) products.  Pluristyx’s unique clinical-grade iPSC lines, derived from